Quantitative PCR and HER2 testing in breast cancer

被引:56
作者
Barberis, Massimo [1 ]
Pellegrini, Caterina [2 ]
Cannone, Maria [1 ]
Arizzi, Carmelo [1 ]
Coggi, Guido [2 ]
Bosari, Silvano [2 ]
机构
[1] IRCCS, Dept Pathol, Milan, Italy
[2] Univ Milan, Osped Maggiore Policlin Mangiagalli & Regina Elen, AOS Paolo & Fdn IRCCS, Dept Med Surg & Dent Sci,Pathol Unit, Milan, Italy
关键词
breast cancer; fluorescent in situ hybridization; FISH; HER2; immunohistochemistry; quantitative real-time RT-PCR; reverse transcription-polymerase chain reaction; tissue microarray;
D O I
10.1309/1AKQDQ057PQT9AKX
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
We performed a technical and cost-effectiveness analysis of quantitative reverse transcription-polymerase chain reaction (Q-RT-PCR) for the assessment of HER2 in breast cancer. We evaluated 44 frozen and 55 formalin-fixed paraffin-embedded (FFPE) breast carcinoma specimens by Q-RT-PCR, immunohistochemical analysis, and fluorescent in situ hybridization (FISH). Immunohistochemical and FISH analyses were performed on individual slides and on tissue microarray. Costs of techniques were calculated to study 1 case and 10 or 40 cases. Q-RT-PCR provided reliable data in frozen and FFPE specimens, which were significantly correlated. HER2 messenger RNA levels were significantly stratified in agreement with immunohistochemical data (P <.05). There was complete concordance between Q-RT-PCR and immunohistochemical results for negative and strongly positive (3 +) cases. The intermediate immunohistochemical group (2+), including FISH+ and FISH- cancers, could also be stratified by Q-RT-PCR. Cost analysis documented the advantage of Q-RT-PCR in all US Food and Drug Administration-approved assays. Our data support the use of Q-RT-PCR for testing breast cancer specimens to select patients for HER2 inhibitory therapy.
引用
收藏
页码:563 / 570
页数:8
相关论文
共 38 条
[1]   External quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme [J].
Bartlett, John M. S. ;
Ibrahim, Merdol ;
Jasani, Bharat ;
Morgan, John M. ;
Ellis, Ian ;
Kay, Elaine ;
Magee, Hilary ;
Barnett, Sarah ;
Miller, Keith .
JOURNAL OF CLINICAL PATHOLOGY, 2007, 60 (07) :816-819
[2]   2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology [J].
Bast, RC ;
Ravdin, P ;
Hayes, DF ;
Bates, S ;
Fritsche, H ;
Jessup, JM ;
Kemeny, N ;
Locker, GY ;
Mennel, RG ;
Somerfield, MR .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (06) :1865-1878
[3]   Feasibility of using tissue microarrays for the assessment of HER-2 gene amplification by fluorescence in situ hybridization in breast carcinoma [J].
Bhargava, R ;
Lal, P ;
Chen, BY .
DIAGNOSTIC MOLECULAR PATHOLOGY, 2004, 13 (04) :213-216
[4]  
Bièche I, 1999, CLIN CHEM, V45, P1148
[5]  
Bijwaard KE, 2001, CLIN CHEM, V47, P195
[6]  
Birner P, 2001, CLIN CANCER RES, V7, P1669
[7]  
Bose S, 2001, Breast J, V7, P337, DOI 10.1046/j.1524-4741.2001.21018.x
[8]  
Bossard C, 2005, ANTICANCER RES, V25, P4679
[9]   Measurement of gene expression in archival paraffin-embedded tissues - Development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay [J].
Cronin, M ;
Pho, M ;
Dutta, D ;
Stephans, JC ;
Shak, S ;
Kiefer, MC ;
Esteban, JM ;
Baker, JB .
AMERICAN JOURNAL OF PATHOLOGY, 2004, 164 (01) :35-42
[10]  
de Cremoux P, 1999, INT J CANCER, V83, P157, DOI 10.1002/(SICI)1097-0215(19991008)83:2<157::AID-IJC2>3.3.CO